OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer Dec 05, 2017 8:00am EST
OncoSec Expands Intellectual Property Estate, Announces Issuance of Patents for ImmunoPulse® Platform Nov 28, 2017 8:00am EST
OncoSec Announces Preclinical Data Demonstrating Multi-Gene Expression Platform for Delivery of Multiple Cancer Immunotherapies at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017 Nov 09, 2017 8:00am EST
OncoSec Announces Positive Updated Long-Term Follow-Up Data from Phase 2 Trial of ImmunoPulse® IL-12 in Combination with Pembrolizumab Demonstrating a Progression Free Survival Rate (PFS) of 57% at 15 months in Predicted Anti-PD-1 Non-Responder Melanoma Patients Nov 08, 2017 7:30am EST
OncoSec Appoints Daniel J. O'Connor as Chief Executive Officer to Lead Next Stage of Growth as a Fully Integrated Late Stage Development and Commercial Company Nov 07, 2017 5:03pm EST
OncoSec Announces Fourth Quarter and Year End Financial Results for Fiscal Year 2017 Oct 25, 2017 4:15pm EDT
OncoSec Closes $7.1 Million Registered Direct Offering Priced At-the-Market and Announces $1.1 Million Registered Direct Offering Priced Above Market Oct 25, 2017 12:46pm EDT
OncoSec Announces $7.1 Million Registered Direct Offering Priced At-the-Market Oct 23, 2017 9:00am EDT
OncoSec Presents Positive Phase 2 Data for ImmunoPulse® IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non-Responder Melanoma Patients Oct 19, 2017 6:00am EDT
